E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
Aorta to pulmonary artery duct |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cardiovascular Diseases [C14] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10034130 |
E.1.2 | Term | Patent ductus arteriosus |
E.1.2 | System Organ Class | 10010331 - Congenital, familial and genetic disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
We aim to identify infants at high risk of developing CLD/Death by utilising the PDAsc, and randomise those infants to early treatment with Ibuprofen versus placebo. We hypothesise that:
• in preterm infants less than 29 weeks gestation; • at high risk of developing CLD/Death (Primary outcome) based on a PDAsc ≥ 5.0; • obtained using echocardiography carried out between 36 and 48 hours of life;
,early treatment with non-steroidal anti-inflammatory drugs (Ibuprofen) compared with placebo will result in a reduction of CLD/Death by 36 weeks post menstrual age (PMA). Infants with a PDAsc < 5 will not be enrolled in the study but will be followed up to discharge to confirm their low risk status.
|
|
E.2.2 | Secondary objectives of the trial |
We will collect information on important secondary outcomes including culture proven sepsis, inotrope and diuretic use, postnatal steroids administration, PDA treatment beyond day 14 of age (including PDA ligation), necrotizing enterocolitis (NEC) with radiological evidence of pneumatosis intestinalis; intraventricular haemorrhage , days on invasive ventilation/continuous positive airway pressure (CPAP)/ supplemental oxygen, hospital days, treated retinopathy of prematurity and periventricular leukomalacia.
In this pilot study we also aim to ascertain issues with recruiting infants and obtaining consent, compliance with the protocol, the rate (if any) of loss to follow up, and the general acceptability, feasibility and compliance of administering the intervention. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
All infants less than 29 weeks admitted to the NICU with a PDA identified on echocardiography between 36 and 48 hours of life will be eligible for inclusion. A comprehensive assessment of PDA significance will be performed using echocardiography to derive a PDA risk score based on this following formula: Infants with a risk score ≥ 5.0 are deemed to be at high risk of developing CLD/Death and will be randomised to either arm
(Gestation in weeks × -1.304) + (PDA diameter in mm × 0.781) + (Left ventricular output in ml/kg/min × 0.008) + (maximum PDA velocity in m/s × -1.065) + (LV a` wave in cm/s × -0.470) + 41, where 41 is the constant of the formula.
|
|
E.4 | Principal exclusion criteria |
The following infants will be excluded:
• lack of consent or study investigators • lethal congenital abnormality or obvious syndrome • pulmonary hypoplasia • active bleeding • known or suspected NEC • platelet count < 100/mm2 • creatinine > 100 µmol/L; neutropenia • oliguria < 1ml/kg/hour • congenital heart disease other than a PDA or a patent foramen ovale • grade 3 or higher IVH
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary outcome of the study is chronic lung disease defined as the need for oxygen at 36 weeks corrected age or and/or death before discharge. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
This will be assessed prior to hospital discharge at 36 weeks corrected age. |
|
E.5.2 | Secondary end point(s) |
The following secondary clinical outcomes will also be obtained: culture proven sepsis, inotrope and frusemide use, postnatal steroids administration, PDA treatment beyond day 14 of age (including PDA ligation), necrotizing enterocolitis (NEC) with radiological evidence of pneumatosis intestinalis; intraventricular haemorrhage assessed on day 7 of age and classified according to Papile Classification, days on invasive ventilation/continuous positive airway pressure (CPAP)/ supplemental oxygen, hospital days, treated retinopathy of prematurity and periventricular leukomalacia. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
This will be assessed prior to hospital discharge at 36 weeks corrected age. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 2 |